BioNxt Solutions (OTCMKTS:BNXTF) versus Esperion Therapeutics (NASDAQ:ESPR) Critical Comparison

Esperion Therapeutics (NASDAQ:ESPR) and BioNxt Solutions (OTCMKTS:BNXTF) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, analyst recommendations, valuation and dividends.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Esperion Therapeutics and BioNxt Solutions, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Esperion Therapeutics	1	6	1	0	2.00
BioNxt Solutions	0	0	0	0	0.00

Esperion Therapeutics currently has a consensus price target of $5.54, suggesting a potential upside of 77.00%. Given Esperion Therapeutics’ stronger consensus rating and higher possible upside, equities analysts clearly believe Esperion Therapeutics is more favorable than BioNxt Solutions.

Volatility and Risk

Esperion Therapeutics has a beta of 0.91, indicating that its stock price is 9% less volatile than the S&P 500. Comparatively, BioNxt Solutions has a beta of 0.69, indicating that its stock price is 31% less volatile than the S&P 500.

Valuation and Earnings

This table compares Esperion Therapeutics and BioNxt Solutions”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Esperion Therapeutics	$403.14 million	2.00	-$22.68 million	($0.17)	-18.41
BioNxt Solutions	$20,000.00	1,962.90	-$5.43 million	($0.04)	-8.01

BioNxt Solutions has lower revenue, but higher earnings than Esperion Therapeutics. Esperion Therapeutics is trading at a lower price-to-earnings ratio than BioNxt Solutions, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Esperion Therapeutics and BioNxt Solutions’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Esperion Therapeutics	-3.66%	N/A	-3.93%
BioNxt Solutions	N/A	N/A	-724.88%

Insider & Institutional Ownership

47.4% of Esperion Therapeutics shares are held by institutional investors. 1.7% of Esperion Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Esperion Therapeutics beats BioNxt Solutions on 8 of the 13 factors compared between the two stocks.

About Esperion Therapeutics

Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C. The company’s products also include NILEMDO, an ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors; and NUSTENDI, a bempedoic acid and ezetimibe tablet to treat elevated LDL-C. The company has license and collaboration agreements with Daiichi Sankyo Co. Ltd to; Otsuka Pharmaceutical Co., Ltd; and Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.

About BioNxt Solutions

BioNxt Solutions Inc. engages in generation drug formulations and delivery system in Korea, Austria, Germany, and Switzerland. The company provides drug delivery methods, such as transdermal patches and oral dissolvable films designed for delivery of neurological medications. It offers point-of-care diagnostic, including covid-19 PCR diagnostic kit, a covid rapid test; peri-implantitis Oral Biosensor, allows early detection of infection associated with dental implants; and H1N1 (Swine Flu) and H5N1 (Avian Flu) oral biosensors for early detection of highly pathogenic influenza a strains. In addition, the company offers psychedelic medicine to treat mental health-related medical conditions, including depression, anxiety, addiction, and trauma-related stress disorder. Further, it provides analytical testing and consulting services. The company was formerly known as XPhyto Therapeutics Corp. and changed its name to BioNxt Solutions Inc. in November 2022. The company was incorporated in 2017 and is headquartered in Vancouver, Canada.